Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Presentation (May 2021)

44 slides from Windtree Therapeutics's investor presentation, May 13, 2021

  1. Slide 1: Windtree Therapeutics Company Overview

    Windtree Therapeutics eR Company Overview XK) , WINDTREE THERAPEUTICS

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company

  3. Slide 3: Windtree Therapeutics Highlights

    Windtree Therapeutics Highlights GS Biopharmaceutical and medical device company with four advanced clinical programs spanning cardiovascular and respiratory disease states (NASDAQ: WINT) GS Clinical programs focused on significant markets with high unmet needs and with supportive regulatory paths:

  4. Slide 4: Windtree Therapeutics Pipeline

    Windtree Therapeutics Pipeline FDA Fast Track Designation Potential for Breakthrough designation FDA, EMA Lead Products Pre- | Phase! | Phase 11 | Phase Ill | Next Milestone Istaroxime (Acute Heart Failure) Istaroxime (Early Cardiogenic Shock) Oral SERCA2a Activators (Chronic HF; potentially HFpEF)

  5. Slide 5: Planned Milestones

    Planned Milestones 03 aa aa a2 03 aa Istaroxime Early Cardiogenic Shock Study postin ; bata, then Istaroxime Acute Heart Failure Study E0P2 Miginto ( (transition to Phase 3)* h3, potential —— partnering Jinical Milestones covio-istung KL4 Surfactant iugrreatment 4 Data & Timing 180: AEROSURF AEROSUR

  6. Slide 6: Istaroxime

    Istaroxime Dual Mechanism SERCA2a Activator Acute Heart Failure and Early Cardiogenic Shock.

  7. Slide 7: Heart Failure — Large, Growing Market But Underserved

    Heart Failure — Large, Growing Market But Underserved The prevalence and mortality of heart failure is high and increasing > 6MU.S., 20M+ worldwide patients Vv #1 cause of U.S. hospitalization in patients > 65 years old; * >1.3M admissions annually (U.S.) ~1.5M admissions annually (E.U.) Vv In-patie

  8. Slide 8: Acute Heart Failure — Significant Unmet Clinical Need

    Acute Heart Failure — Significant Unmet Clinical Need "= Clinical objectives for AHF = Current approaches to acutely improve patient management include: cardiac function are associated with * Relieve pulmonary congestion unwanted effects: and general edema (e.g. “dry * Heart rhythm disturbances out”

  9. Slide 9: Istaroxime — Novel First-in-Class Therapy

    Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart Inhibition of the sodium. 2 Stimulation of SERCA2a activity ‘ . enhances calcium reuptake resulting in potassium pumpandeffectson [StQrOXIME improvement of

  10. Slide 10: Istaroxime AHF Phase 2a & 2b Studies - Summary

    Istaroxime AHF Phase 2a & 2b Studies —- Summary Multicenter, double blind, placebo-controlled, parallel group in 240 patients mB Oh © n=120 Dosing= 6 hour Phase one patients 0.5, 1, 1.5 ye/ts/min Infusion Phase n=120 Dosing= 24 hour 2b ADHF Patients 0.5, 1.0 ue/ig/min Infusion (dyspnea plus need for

  11. Slide 11: Primary Endpoint Achieved

    Primary Endpoint Achieved Significant Changes in E/e' Ratio) and Stroke Volume istaroxime 0.5 ug/kg/min vs. placebo istaroxime 1.0 pg/kg/min vs. placebo 20 20 19 19 oo co 10 9% ge Bao 40 y eae Sto Fe 32 50 so Tafusion period * infusion ped = * pvalues $0,038 Secine Shows hows Bows Beene Shaws 2éhous

  12. Slide 12: Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve

    Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve istaroxime 0.5 ug/kg/min vs. placebo istaroxime 1.0 pg/kg/min vs. placebo 2 ————— 9 i Systolic = & Blood = 3 Pressure = 2 (sp) 6. «| hake t 5 TP yvalue=0.011, * p-values s0:006 woth gta otto wah gre are? pe? 9 Pr

  13. Slide 13: Heart Rate Decreased and No Increases in Cardiac Troponins

    Heart Rate Decreased and No Increases in Cardiac Troponins istaroxime 0.5 ug/kg/min vs. placebo istaroxime 1.0 pg/kg/min vs. placebo a ° £ si—aa 6 S$ __infustonperid infusion period Bo Heart . E23 Rate 3 i it : o-¢ 2 4 + pevalue = Bae * prvalue= 0.014 ‘> Lauer Sas as sae oS SS SS SE Ee Oe =-9- Place

  14. Slide 14: Favorable Profile Observed with 24-hour Holter Monitoring

    Favorable Profile Observed with 24-hour Holter Monitoring May Have Protective Effect on Cardiac Arrhythmias Clinically Significant Arrhythmias Clinically Significant Arrhythmias 120% —s05% 250% i = > 20.0% 20.0% 20.0% 100% si ee 15.0% I se 60x Loox r om ton 100% Daal Z 8% 28% 2 50% oon oo% rhe om Le

  15. Slide 15: Istaroxime — Acute Heart Failure Next Steps

    Istaroxime — Acute Heart Failure Next Steps Objective: Optimize therapy and employ study enrichment strategies to create strong Phase 3 and partnership position Execute an additional study designed to complete Phase 2 and inform Phase 3 - 300 patients, 75 centers globally* Enrich therapeutic impact

  16. Slide 16: Istaroxime Early Cardiogenic Shock

    Istaroxime Early Cardiogenic Shock Additional potential indication in active clinical development

  17. Slide 17: Early Cardiogenic Shock Treatment

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Approval Pathway Cardiogenic shock is a severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high PCWP and decreased urine output > No satisfactory pharmacolog

  18. Slide 18: Changes in SBP — Phase 2a and 2b Dose Groups

    Changes in SBP — Phase 2a and 2b Dose Groups Istaroxime Has Potential to Improve Blood Pressure and Organ Perfusion 20.0 18.0 16.0 14.0 12.0 10.0 8.0 6.0 4.0 2.0 0.0 2a Study 2b Study 2a Study 2b Study 2a Study SBP Mean Change + SE (mmHg) 0.5 yg/kg/min 1.0 ug/kg/min 1.5 jig/kg/min Study/Dose ‘Mean S

  19. Slide 19: Istaroxime Early Cardiogenic Shock in Severe AHF Study

    Istaroxime Early Cardiogenic Shock in Severe AHF Study Goal: * Improve SBP with acceptable safety profile > Increased systolic and diastolic cardiac function without increasing heart rate, risk for arrythmias or myocardial oxygen demand * Support a breakthrough therapy regulatory application Ongoing

  20. Slide 20: Next Generation, Oral SERCA2a Activators

    Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCA2a Dual Mechanism, (SERCA2a Activators & Na+/K+) Compounds * Oral & i.v. therapies for chronic heart = “Next generation Istarox

  21. Slide 21: Summary

    Summary Potential to Create Value = Acute heart failure — large market with significant unmet need * Istaroxime appears to be the only drug in phase 2 or phase 3 development for AHF treatment = Istaroxime—dual-mechanism therapy with positive phase 2a and 2b trial outcomes: ¥ Improved cardiac functio

  22. Slide 22: Lyo Lucinactant

    Lyo Lucinactant Synthetic KL4 Surfactant Lung Injury in Og COVID-19 Patients ® rh

  23. Slide 23: COVID-19 and ARDS Have Significant Negative Impact on Surfactant-Related Lung Function

    COVID-19 and ARDS Have Significant Negative Impact on Surfactant- Related Lung Function i a Uses angiotensin- ‘ACE2is surface molecule on converting enzyme 2 alveolar Type 2 lung cells ~ (ACE2) for entry into host the source of surfactant cells RS. Surfactant is necessary for lungs to stay inflated

  24. Slide 24: Surfactant Administration in Severe COVID-19 Lung Injury May Have Potential to Provide Significant Benefits

    Surfactant Administration in Severe COVID-19 Lung Injury May Have Potential to Provide Significant Benefits = Synthetic KL4 surfactant may mitigate surfactant deficiency and resist widespread surfactant destruction that can occur as a result of COVID-19 = Synthetic KL4 surfactant removes any immunol

  25. Slide 25: Phase 2 Study of Lucinactant for Treatment of COVID-19

    Phase 2 study of Lucinactant (KL4 Surfactant) for Treatment of COVID-19 Objective: demonstrate changes in physiological parameters in COVID-19- associated lung injury and ARDS &_ ¢ Upto 20 patients from 4-5 US sites S — Led by investigators at Brigham & Women’s and Duke Medical Center ar © Dosing th

  26. Slide 26: AEROSURF

    AEROSURF Synthetic KL4 Surfactant with Proprietary Aerosol Delivery System Respiratory Distress Syndrome (RDS)

  27. Slide 27: Respiratory Distress Syndrome (RDS)

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways = surfactant helps keep lungs open between breaths and gas exchange = Premature infants experience respiratory distress syndrome (“RDS”) due to lungs lacking endogenous surfactant = Physicians must choose between invasive surfactant deli

  28. Slide 28: AEROSURF — Potential to Impact the Clinical Course of RDS

    AEROSURF® — Potential to Impact the Clinical Course of RDS Building Evidence From Nearly 400 Patients Studied Long-Term Outcomes Reduced Rates and Severity of BPD 2 WINDTREE ae Noninvasive RDS treatment Improved Respiratory Study results show Parameters evidence of potential impact on clinical cours

  29. Slide 29: AEROSURF Program Evolution and Strategy

    AEROSURF® Program Evolution and Strategy Mitigating Risks and Strengthening Our Approach “1 Execute small (n=~80 - 90) Bridging Study to transition to EOP2 / Phase 3: * Demonstrate that new ADS works and supplement phase 2 data + Optimize dosing with more drug and shorter repeat intervals Y Transiti

  30. Slide 30: Financial Summary & Capitalization as of March 31, 2021

    Financial Summary & Capitalization as of March 31, 2021 Cash & Equivalents of ~$38.5 million Bank Debt: ~$2.4M credit facility due in March 2022 B WINDTREE Common Equivalents Secures as of March 31, 2021 Common Stock 26,257,065 Options (WAEP $11.39) 3,239,728 Warrants (WAEP $9.43) 16,628,802 Fully D

  31. Slide 31: Strategy for Value Generation

    Strategy for Value Generation se we WINDTREE THERAPEUTICS” Strong Clinical Execution to Deliver Milestones: Execute well our late-stage clinical programs for achievement of milestones and news flow that may be growth catalysts G Transactions: * Secure focused BD transactions for deal revenue and non

  32. Slide 32: Striving to Deliver Hope for a Lifetime!

    “Striving to Deliver Hope for a Lifetime!” S@ winotREe ae

  33. Slide 33: Appendix

    Appendix SB winvtRee BE merrcunce

  34. Slide 34: Acute Heart Failure

    Acute Heart Failure Significant Healthcare Issue with Significant Unmet Clinical Need = Patients with low blood pressure (SBP) and peripheral hypoperfusion are high risk, challenging patients. These patients are also generally resistant to diuretic therapy and often discharged in a sub-optimal state

  35. Slide 35: Istaroxime Phase 2a (HORIZON-HF) Study

    Istaroxime Phase 2a (HORIZON-HF) Study Primary Endpoint: PCWP Significant Improvements = Multicenter, double blind, placebo- E controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU = Hospitalized with AHF, with criteria including: © LVEF < 35% * SBP 90-150 mmHg

  36. Slide 36: Istaroxime Phase 2b Adverse Events

    Istaroxime Phase 2b Adverse Events istaroxime 0.5 istaroxime 1.0 me/Ke/min me/Ke/min (n=41) {n=40) All adverse events 23 (59.0%) 31 (75.6%) 33 (82.5%) ‘Adverse events leading to discontinuation Pooled placebo {n=39) 1(2.6%) . 4 (10.0%) Serious adverse events 2(5.1%) 2 (4.9%) 6 (15.0%) Cardiac death

  37. Slide 37: KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical H5N1 Study

    KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical HSN1 Study H5N1 Study — With and Without Anti-Viral Agent = Ferrets Infected with highly pathogenic avian (H5N1) influenza = Results in significant viral and inflammation related lung damage that is substantially ameliorated by KL4 sur

  38. Slide 38: Evidence of KL4 Surfactant Potential Utility in COVID-19

    Evidence of KL4 Surfactant Potential Utility in COVID-19 Demonstrated Utility Across Various Respiratory Distress We have been evaluating the applicability of KL4 surfactant for multiple etiologies of lung injury as well as pandemic influenza long before the COVID-19 pandemic GR ee Demonstrated Util

  39. Slide 39: References Supporting Utilization of KL4 Surfactant for the Treatment of Lung Injury

    References Supporting Utilization of KL4 Surfactant for the Treatment of Lung Injury 1. Hottmann M, H. Klene-Webey, eta (2020) "Thenovelcoronavitus2019(201rCoV) uses the SARS-coronaviusrecertor ACE2 andthe eller protesseTMPRSS2 for ent itotarget <ells10.1201/202001.3.929082 "bof: 2020.01 31, 929002

  40. Slide 40: Surfactant in ARDS References

    Surfactant in ARDS References “Gregory, Steinberg KP, SprageR, Gadek JE, Hyer=TM, Longmore WA, etal. ovine surfactanttherapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 1997;155:1309-1315 ‘WiedemannH, Baughman, de Boisblanc€, etal, A multi centered tal inhuman s

  41. Slide 41: Respiratory Distress Syndrome (RDS)

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways Premature infants experience RDS due to underdeveloped lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and proper gas exchange Initial treatment options include 2 a =~ invasive and noninvasive method

  42. Slide 42: Windtree Technology Platform — AEROSURF

    Windtree Technology Platform — AEROSURF® Proprietary Synthetic KLa Surfactant Structurally similar to human lung surfactant Utilizing pressure and heated capillary has demonstrated Liquid KLa surfactant (intratracheal instillate) ally ionsermeciiea Miaantectane for RDS approved by the FDA Lyophilize

  43. Slide 43: Transformative Potential of AEROSURF

    Transformative Potential of AEROSURF® Surfactant Therapy Reversing surfactant deficiency has a profound positive impact on respiration ‘Surfactant therapy delivers near-immediate clinical improvement BPD Infection, ventilator-induced pneumonia RISKS cord damage, asthma, lung damage nCPAP. Respirator

  44. Slide 44: Business Development Focus

    Business Development Focus We are actively engaged in discussions with multiple companies with a proactive focus as follows: Cardiovascular Partner — China Pure SERCA2a Pharma Partner — Global AEROSURF® / KL4 Licensing ex-Asia Mid-term Heart Failure Portfolio Partner — Global (Data & EOP2) Rosta Out

Windtree Therapeutics — Investor Presentation (May 2021) on 6ix